RenovoRx, Inc.
RNXTHealthcare|Biotechnology|US
$1.13
-0.06 (-5.04%)
DCF Value
$0.89
Tangible Book / Share
$0.19
Cash / Share
$0.22
Financials
Financial Snapshot
Market Cap
$51.0M
Enterprise Value
$40.8M
Revenue (TTM)
$2.8M
Net Income (TTM)
-$13.0M
Cash & Investments
$10.4M
Net Cash
$10.2M
Free Cash Flow (TTM)
-$12.2M
Operating CF (TTM)
-$12.1M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$10.4M
Quarterly Burn
$3.0M
Monthly Burn
$1.0M
Est. Runway
~3.4 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.1M | $1.8M | $15.2M | $6.4M | $1.2M | $7.2M | $7.0M | $10.4M | |
| Operating Cash Flow | -$3.4M | -$3.5M | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M | -$12.1M | |
| Free Cash Flow | -$3.4M | -$3.5M | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M | -$12.2M | |
| Capital Expenditure | $0.00 | $0.00 | -$15.0K | $0.00 | $0.00 | -$12.0K | -$2.0K | -$90.0K | |
| Financing Cash Flow | $0.00 | $3.2M | $19.3M | $42.0K | $5.0M | $15.1M | $10.8M | $12.6M |
R&D Spending
R&D (TTM)
$5.2M
R&D Intensity
186.2%
R&D Growth vs Prior
-17.5%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $43.0K | $1.1M | $2.8M | |
| R&D Expense | $3.0M | $2.4M | $3.0M | $4.3M | $5.7M | $6.0M | $6.3M | $5.2M | |
| R&D % of Revenue | — | — | — | — | — | 14011.6% | 558.2% | 186.2% | |
| SG&A | $899.0K | $818.0K | $2.6M | $5.6M | $5.7M | $5.0M | $7.0M | $10.7M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $43.0K | $1.1M | $2.8M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $327.0K | $443.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $43.0K | $796.0K | $2.3M | |
| R&D | $3.0M | $2.4M | $3.0M | $4.3M | $5.7M | $6.0M | $6.3M | $5.2M | |
| SG&A | $899.0K | $818.0K | $2.6M | $5.6M | $5.7M | $5.0M | $7.0M | $10.7M | |
| Operating Income | -$3.9M | -$3.2M | -$5.7M | -$9.9M | -$11.4M | -$11.0M | -$12.5M | -$13.4M | |
| Interest Expense | $0.00 | $590.0K | $904.0K | $57.0K | $108.0K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$3.8M | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M | -$13.0M | |
| Net Income | -$3.8M | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M | -$13.0M | |
| EPS (Diluted) | -0.22 | -0.25 | -0.40 | -0.54 | -0.50 | -0.37 | -0.32 | -0.32 | |
| EBITDA | -$3.8M | $0.00 | -$5.5M | -$9.8M | -$10.1M | -$8.8M | -$11.2M | -$12.6M | |
| Shares Out. (M) | 17.32 | 17.32 | 17.87 | 18.10 | 20.58 | 23.61 | 35.33 | 48.19 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $1.8M | $15.2M | $4.4M | $1.2M | $7.2M | $7.0M | $10.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $2.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.3M | $1.9M | $16.3M | $7.3M | $1.5M | $7.8M | $7.9M | $11.8M | |
| Total Assets | $2.3M | $1.9M | $16.3M | $7.3M | $1.5M | $8.1M | $8.1M | $12.4M | |
| Total Current Liabilities | $805.0K | $4.1M | $938.0K | $1.1M | $1.2M | $1.9M | $2.0M | $2.1M | |
| Long-Term Debt | $0.00 | $23.0K | $0.00 | $0.00 | $0.00 | $0.00 | $107.0K | $225.0K | |
| Total Liabilities | $805.0K | $16.6M | $938.0K | $1.1M | $4.5M | $3.6M | $2.7M | $3.2M | |
| Stockholders' Equity | $1.5M | -$14.7M | $15.3M | $6.2M | -$3.0M | $4.5M | $5.4M | $9.3M | |
| Retained Earnings | -$11.2M | -$15.0M | -$21.3M | -$31.2M | -$41.4M | -$50.2M | -$61.4M | -$71.5M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.4M | -$3.5M | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M | -$12.1M | |
| Capital Expenditure | $0.00 | $0.00 | -$15.0K | $0.00 | $0.00 | -$12.0K | -$2.0K | -$90.0K | |
| Free Cash Flow | -$3.4M | -$3.5M | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M | -$12.2M | |
| Investing Cash Flow | -$1.0K | $0.00 | -$15.0K | -$2.0M | $2.0M | -$12.0K | -$2.0K | -$90.0K | |
| Financing Cash Flow | $0.00 | $3.2M | $19.3M | $42.0K | $5.0M | $15.1M | $10.8M | $12.6M | |
| Issuance of Stock | $0.00 | $43.0K | $14.6M | $42.0K | $5.0M | $15.0M | $12.1M | $10.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $3.2M | $2.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $38.0K | $50.0K | $147.0K | $644.0K | $1.1M | $1.2M | $1.3M | $1.6M | |
| Net Change in Cash | -$3.4M | -$329.0K | $13.4M | -$10.8M | -$3.2M | $6.0M | -$130.0K | $360.0K |
Dilution Tracker
Shares outstanding grew 104.0% over 5 years — significant dilution
Shares Outstanding
45M
5-Year Share Growth
+104.0%
Stock Issuance (TTM)
$10.0M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 17.32 | 17.32 | 17.87 | 18.10 | 20.58 | 23.61 | 35.33 | 48.19 | |
| Change vs Prior % | — | 0.0% | 3.1% | 1.3% | 13.7% | 14.7% | 49.7% | 36.4% | |
| Stock Issuance | $0.00 | $43.0K | $14.6M | $42.0K | $5.0M | $15.0M | $12.1M | $10.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $38.0K | $50.0K | $147.0K | $644.0K | $1.1M | $1.2M | $1.3M | $1.6M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 100.0% | 70.9% | 84.0% | |
| Operating Margin % | — | — | — | — | — | -25511.6% | -1114.0% | -483.9% | |
| Net Margin % | — | — | — | — | — | -20497.7% | -994.5% | -469.0% | |
| EBITDA Margin % | — | — | — | — | — | -20497.7% | -994.3% | -454.0% | |
| FCF Margin % | — | — | — | — | — | -21248.8% | -977.3% | -440.4% | |
| ROE % | -262.0% | 25.9% | -41.2% | -160.5% | 341.1% | -196.8% | -206.0% | -149.0% | |
| ROA % | -169.1% | -198.4% | -38.8% | -136.1% | -698.0% | -108.6% | -138.0% | -104.7% | |
| ROIC % | -265.9% | -547.7% | -36.9% | -161.4% | -3916.2% | -174.8% | -200.5% | -129.8% | |
| R&D / Revenue % | — | — | — | — | — | 14011.6% | 558.2% | 186.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2511.6% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1751.2% | |
| Operating Income | 0.0% | 17.8% | -77.0% | -75.5% | -14.5% | 3.7% | -14.0% | |
| Net Income | 0.0% | 1.1% | -66.5% | -56.4% | -3.5% | 13.9% | -26.7% | |
| EPS (Diluted) | 0.0% | -13.6% | -60.0% | -35.0% | 7.4% | 26.0% | 13.5% | |
| Operating Cash Flow | 0.0% | -5.3% | -67.7% | -48.9% | -16.4% | 11.0% | -20.3% | |
| Free Cash Flow | 0.0% | -5.3% | -68.1% | -48.6% | -16.4% | 10.9% | -20.1% | |
| R&D Expense | 0.0% | -20.4% | 27.4% | 41.5% | 31.8% | 6.3% | 4.0% | |
| SG&A Expense | 0.0% | -9.0% | 221.8% | 114.6% | 1.4% | -12.9% | 41.1% | |
| Total Assets | 0.0% | -15.7% | 750.9% | -55.4% | -79.8% | 453.8% | -0.3% | |
| Book Value / Share | 0.0% | -1100.4% | 201.5% | -60.4% | -142.8% | 230.1% | -19.1% | |
| Debt | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | -23.7% | |
| Diluted Shares | 0.0% | 0.0% | 3.1% | 1.3% | 13.7% | 14.7% | 49.7% |
Valuation
P/E (TTM)At Loss
P/S18.37
P/B5.87
10Y Low / Med / High5.47 / 6.80 / 85.85
EV/EBITDAAt Loss
EV/Revenue14.70
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.89
Tangible Book / Share
$0.19
Net Current Assets / Share
$0.19
Graham Net-Net
$0.16
Cash / Share
$0.22
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -33.00 | -29.04 | -12.10 | -4.35 | -4.58 | -3.49 | -2.63 | -3.57 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 708.18 | 26.43 | 18.37 | |
| P/B Ratio | 85.85 | -8.58 | 5.63 | 6.90 | -15.71 | 6.80 | 5.47 | 5.87 | |
| EV/EBITDA | -32.21 | 0.00 | -13.01 | -3.88 | -4.54 | -2.67 | -2.05 | -3.24 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 548.27 | 20.37 | 14.70 |
Analyst Estimates & Quality
Altman Z-Score
-0.52
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.9M | $11.5M | $33.5M |
| Net Income | -$9.3M | -$4.9M | $1.3M |
| EPS | $-0.26 | $-0.14 | $0.04 |
| # Analysts (EPS) | 2 | 2 | 2 |
Revenue Segments
By Product
| Segment | 2024 | 2025 |
|---|---|---|
| Other Operating Segment | $43.0K | $1.1M |